B. HIRSCHEL, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: Prophylaxis of malaria by amodiaquine is dangerous (1, 2). At least 20 cases of amodiaquine-associated agranulocytosis have been discovered so far in Switzerland, and 12 of these were associated with hepatitis. Six were fatal (Drs. Neftel and Somaini. Personal communication). The following case reports suggest that the drug is not only toxic but also may not prevent malaria even in areas of low chloroquine resistance.
Patient 1: A 32-year-old man visited Cameroon from 24 December 1985 to 10 January 1986. He had taken amodiaquine (Camoquin; Parke-Davis, Morris Plains, New Jersey), 400 mg/wk, until January 17th. On the
HIRSCHEL B. Amodiaquine and Hepatitis. Ann Intern Med. 1986;105:467. doi: https://doi.org/10.7326/0003-4819-105-3-467_1
Download citation file:
Published: Ann Intern Med. 1986;105(3):467.
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use